Quanterix Simoa Technology Powers Multiple Sclerosis Research with More Than 50 Presentations at ECTRIMS 2019
Record-breaking number of presentations and abstracts at International Multiple Sclerosis conference demonstrates promise and relevance of Neurofilament light chain (Nf-L) as a reliable disease biomarker for MS
“The rapidly growing body of scientific research demonstrating Nf-L as a novel biomarker for MS continues to validate the potential of Nf-L for changing the way MS patients are diagnosed, treated and monitored,” said
According to the National
To learn more about
To learn more about Quanterix’ Nf-L assay, click here.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding the completion of the proposed public offering. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected and
Erin Smith, 617-502-4300